Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Novartis
$8.7 billion |
| gptkbp:acquisitionYear |
2018
|
| gptkbp:focusesOn |
gene therapy
|
| gptkbp:formerName |
gptkb:Bamboo_Therapeutics
|
| gptkbp:foundedIn |
2010
|
| gptkbp:founder |
gptkb:John_Carbona
|
| gptkbp:headquartersLocation |
gptkb:Bannockburn,_Illinois,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
AveXis
|
| gptkbp:indication |
spinal muscular atrophy
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
gptkb:Sean_Nolan
|
| gptkbp:notableProduct |
gptkb:Zolgensma
|
| gptkbp:parentCompany |
gptkb:Novartis
|
| gptkbp:productApprovalYear |
2019
|
| gptkbp:productApprovedBy |
gptkb:FDA
|
| gptkbp:specializesIn |
rare neurological genetic diseases
|
| gptkbp:subsidiary |
gptkb:Novartis
|
| gptkbp:website |
https://www.avexis.com/
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|